New respiratory syncytial virus immunization products in low- and middle-income countries: potential for cost-effective impact on a high burden of disease in young infantsRespiratory syncytial virusMaternal vaccineInfant monoclonal antibodyBurdenCost effectivenessLow- and middle-income countries...
The large global burden of respiratory syncytial virus (RSV) respiratory tract infections in young children and older adults has gained increased recognition in recent years. Recent discoveries regarding the neutralization-specific viral epitopes of the pre-fusion RSV glycoprotein have led to a shift fr...
A. et al. Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am. J. Epidemiol. 89, 435–448 (1969). Article CAS PubMed Google Scholar Chin...
Respiratory syncytial virus (RSV) is one of the leading causes of hospitalization for acute respiratory distress in infants and young children; however, it is also a significant threat to older adults and those with compromised immune systems. In 2015, there were an estimated 1.5 million cases ...
Nirsevimab for infant RSV prevention was introduced in some Northern Hemisphere countries during 2023. Chile was first to implement a universal countrywide immunization strategy following cost-effectiveness projections in the Southern Hemisphere. This strategy included all newborns born after April 1st, ...
A.: Comparison of enzyme-linked immunosorbent assay and neutralization techniques for measurement of antibody to respiratory syncytial virus: Implications for parenteral immunization with live virus vaccine. Infect. Immun.37, 160–165 (1982). Google Scholar Bennett, C. R., Hamre, D.: Growth and...
Immunization☆ TraceyGoodman, ...JennyWalldorf, inReference Module in Biomedical Sciences, 2023 Respiratory syncytial virus Respiratory syncytial virus(RSV) is a leading cause oflower respiratory tract infectionand hospitalization inyoung childrenglobally, causing an estimated 3.6 million hospitalizations and ...
Respiratory Syncytial Virus Immunization in Sakarya, Turkey Background: Respiratory Syncytial Virus (RSV) is an important respiratory agent causing acute respiratory tract infections in every age group, especially below two-year old infants. Congenital heart disease and prematurity are the leadin... N...
respiratory syncytial virus immune globulin intravenous a preparation of immunoglobulin G from pooled adult human plasma selected for high titers of antibodies against respiratory syncytial virus; used for passive immunization of infants and young children. Rh0(D) immune globulin a specific immune globuli...
is indicated by the finding that immunization with a vaccinia recombinant bearing the respiratory syncytial virus internal Nnucleoproteinexpedites recovery. Furthermore, respiratory syncytial virus is a much less effective inducer ofinterferonsynthesis in normal infants than are influenza andparainfluenzaviru...